Navigation Links
Trellis Bioscience Awarded SBIR Grant to Advance CMV Program
Date:8/16/2012

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2012 /PRNewswire/ -- Trellis Bioscience LLC, a private company discovering and developing novel human antibody therapeutics for the treatment of infectious disease and cancer, has been awarded a Small Business Innovation Research (SBIR) fast-track grant to advance its native human antibody against cytomegalovirus (CMV), CMV345, through preclinical development towards an Investigational New Drug (IND) application filing. The four-year, $3.3 million grant is administered by the National Institute of Allergy and Infectious Disease (NIAID) and will support manufacturing, toxicity testing, and further documentation of efficacy including mechanism of action studies.

"Trellis has successfully deployed our proprietary CellSpot technology to discover four superlative antibodies targeting high-impact infectious diseases, including CMV, RSV and Group 1 and Group 2 Influenza," said Stote Ellsworth, President and CEO of Trellis. "This substantial SBIR funding provides validation of the strength of our program and allows us to advance our CMV product candidate towards human clinical testing, building value and reducing risk. By staying focused on rare antibody discovery and preclinical development, we stick with what we do best."

CMV infection in pregnant women who have not previously been exposed to the virus is the leading non-genetic cause of birth defects. To date, none of the multiple vaccine efforts have yielded a product with better than 50 percent reduction in fetal transmission. Trellis' lead high-affinity native human monoclonal antibody for this indication, CMV345, is intended to neutralize transmission of CMV to the fetus. Recently published research established striking efficacy for hyperimmune globulin enriched for antibodies against CMV, reducing the incidence of birth defects in sero-negative mothers from 43 percent to 13 percent with a P-value of less than 0.01.1 In studies that supported the company's SBIR grant application, Trellis' single antibody CMV345 demonstrated dramatically greater potency and breadth of activity when compared to the same commercial immune globulin product. These initial data suggest that single antibody therapy such as CMV345 is capable of blocking viral infection of all relevant cell types, including critical fibroblast cell types which other published antibodies fail to protect. 

CMV345 is also applicable in transplant indications where CMV is the leading infectious disease cause of morbidity and transplant loss. Published studies point to favorable transplant outcomes for patients who are fortunate to have even low concentrations of CMV345-like antibodies in their serum antibody repertoire.2,3

CMV345 was discovered utilizing Trellis' CellSpot platform, which excels at rapidly identifying and isolating ultra-rare, high-quality native human antibodies directly from blood samples as well as other antibody library sources. The CellSpot technology enables high-throughput screening of human B cells in a multiplexed format based on predetermined selection criteria such as specificity, affinity and cross-reactivity. Leveraging CellSpot, Trellis has successfully discovered monoclonal antibody candidates addressing CMV, respiratory syncytial virus (RSV), and Influenza Group 1 and Group 2.  Current CellSpot discovery programs are addressing methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus A (GAS), and a new anti-cancer target in collaboration with the National Cancer Institute (NCI).

About Trellis Bioscience
Trellis is a venture-funded therapeutic antibody company formed around a breakthrough, high throughput discovery platform capable of isolating ultra-rare therapeutic-grade antibodies directly from the blood cells of humans and other antibody library sources. Trellis' CellSpot technology has generated a robust pipeline of early-stage programs targeting respiratory syncytial virus (RSV), cytomegalovirus (CMV), influenza, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus A (GAS) and cancer.  For more information about Trellis Bioscience, please visit the company's website at www.trellisbio.com.

1 Visentin et al, Clin Infect Dis. 2012 Aug ;55(4) :497-503
2 Ishibashi et al, Transpl Infect Dis. 2011 Jun; 13(3):318-23
3 Ishibashi et al, Clin Infect Dis. 2007 Jul 1 ;45(1) :60-7


'/>"/>
SOURCE Trellis Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
2. Neurocrine Biosciences Reports Second Quarter 2012 Results
3. Roka Bioscience Kicks Off Atlas on Tour, a Mobile Demonstration Vehicle for the Food Safety Industry, at IAFP
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
6. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
7. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
8. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
9. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
10. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
11. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):